Akari Therapeutics AKTX 深 沪
已收盘 08-07 16:00:00 美东时间
7.00
-1.010
-12.61%
华盛通- 最 高8.0955
- 今 开7.98
- 成交量 2.22万股
- 最 低 7.00
- 昨 收 8.01
- 总市值 41.54万
- 52周最高 29.32
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 0.1201
- 委 比 -95.12%
- 总股本 5.93万
- 历史最高 250.00
- 量 比 0.89
- 振 幅 13.68%
- 历史最低 0.00
- 每 手 1
- 风险率 4.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS -15.6%
05-26 18:00
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics shares are surging after preclinical data showed AKTX‑101 synergized with KRAS inhibition in pancreatic cancer models.
05-22 23:17
Akari Therapeutics Commences $5.5M Private Placement
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private
05-21 20:34
Akari Therapeutics Granted European Patent For Proprietary ADC Payload Platform Technology
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the grant of a major European patent that
05-12 20:35
Maxim Group Downgrades Akari Therapeutics to Hold
Maxim Group analyst Jason McCarthy downgrades Akari Therapeutics (NASDAQ:AKTX) from Buy to Hold.
04-08 21:22
Akari Therapeutics Collaborates With WuXi XDC Over Development Of Novel PH1 Payload
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads announced a strategic partnership with WuXi XDC, a
04-06 20:46
Akari Therapeutics Appoints Kameel D. Farag As Interim Chief Financial Officer
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the appointment of Kameel D. Farag as its Interim Chief Financial
2025-11-18 21:41
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Akari Therapeutics received an Indian patent for its immuno-oncology PH1 payload, enhancing its global IP and targeting India's rising cancer rates. PH1 inhibits RNA splicing, killing cancer cells and boosting the immune system, with applications across various cancers. The company aims to expand its ADC technology globally.
2025-06-18 12:50
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Akari Therapeutics, a leading oncology biotech company, introduces a video featuring its new Head of Business Development, Mark F. Kubik, highlighting its innovative ADC platform targeting cancer. Its lead candidate, AKTX-101, uses a novel PH1 payload to disrupt RNA splicing, showing significant activity and survival benefits in preclinical studies. The company continues advancing its lead asset and exploring new targets.
2025-05-29 13:15
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Akari Therapeutics CEO Abizer Gaslightwala will present at a virtual biotech investment webinar on May 29 at 2:00 PM ET. Akari is developing next-generation payload ADCs, with lead candidate AKTX-101 targeting Trop2 receptor and utilizing a novel spliceosome inhibitor payload PH1. The company highlights preclinical success of AKTX-101, demonstrating significant activity, prolonged survival, and potential synergy with checkpoint inhibitors.
2025-05-22 13:00
